David R Spigel1, Tarek M Mekhail2, David Waterhouse3, Terence Hadley4, Charles Webb5, Howard A Burris1, John D Hainsworth1, F Anthony Greco1. 1. a Sarah Cannon Research Institute/Tennessee Oncology, PLLC , Nashville , Tennessee , USA. 2. b Florida Hospital Cancer Institute , Orlando , Florida , USA. 3. c Oncology Hematology Care/US Oncology , Cincinnati , Ohio , USA. 4. d Norton Cancer Institute , Louisville , Kentucky , USA. 5. e Baptist Hospital East , Louisville , Kentucky , USA.
Abstract
BACKGROUND: We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC. METHODS: Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m2 IV, and carboplatin AUC = 6 IV every 21 days. After 6 cycles, maintenance therapy with panitumumab and pemetrexed was administered every 21 days until progressive disease or unacceptable toxicity. RESULTS: 29 of 66 patients (44%) had objective responses. The median TTP was 6 months; median overall survival (OS) was 17 months. Panitumumab increased treatment-related toxicity, notably skin rash. CONCLUSIONS: The addition of panitumumab increased toxicity, and had no discernible impact on efficacy.
BACKGROUND: We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC. METHODS:Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m2 IV, and carboplatin AUC = 6 IV every 21 days. After 6 cycles, maintenance therapy with panitumumab and pemetrexed was administered every 21 days until progressive disease or unacceptable toxicity. RESULTS: 29 of 66 patients (44%) had objective responses. The median TTP was 6 months; median overall survival (OS) was 17 months. Panitumumab increased treatment-related toxicity, notably skin rash. CONCLUSIONS: The addition of panitumumab increased toxicity, and had no discernible impact on efficacy.